Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era

Immune checkpoint inhibitors restart and maintain cancer-immunity circulation to normalize the anti-tumor immunity.Currently, anti-PD-1/PD-L1 antibodies, as new milestone in immunotherapy, have significantly improved the prognosis of patients with various malignant tumors.However, anti-PD-1/PD-L1 antibody alone exhibited a low response rate, and th

read more

The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients Who Become Clinically Node-Negative Following Neo-Adjuvant Chemotherapy: A Literature Review

Background: In clinically node-positive (cN+) breast cancer (BC) patients who become clinically node-negative (cN0) following neoadjuvant chemotherapy (NACT), sentinel lymph node biopsy (SLNB) after lymphatic mapping with lymphoscintigraphy is not widely accepted; therefore, it has become a topic of international debate.Objective: Our literature re

read more